热门资讯> 正文
X4 Pharmaceuticals宣布战略重组,裁员50%,预计每年节省1300万美元的成本
2025-09-17 19:12
- Organizational restructuring including a 50% reduction in workforce that is anticipated to result in annualized cost savings of approximately $13M
- John Volpone appointed Chief Operating Officer, in addition to his current role as President
- Dr. Adam Craig, Executive Chairman, to have oversight over clinical development
风险及免责提示:以上内容仅代表作者的个人立场和观点,不代表华盛的任何立场,华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前,应结合自身情况,考虑投资产品的风险。必要时,请咨询专业投资顾问的意见。华盛不提供任何投资建议,对此亦不做任何承诺和保证。